Key result
Multiple variant alleles in VKORC1 and CYP2C9 significantly increased the risk of overanticoagulation (INR >4) in frail elderly inpatients initiating warfarin (OR 12.8; 95% CI 2.73-60.0).
Why the study?
Do genetic variants (VKORC1, CYP2C9, EPHX1, CYP4F2) predict warfarin maintenance dose and overanticoagulation risk in frail elderly inpatients?
Cohort (n=300)
Do genetic variants (VKORC1, CYP2C9, EPHX1, CYP4F2) predict warfarin maintenance dose and overanticoagulation risk in frail elderly inpatients?
Odds Ratio: 12.8 (95% CI 2.73–60)
Genetic factors significantly influence warfarin dose requirements and the risk of overanticoagulation in frail, elderly inpatients, highlighting the potential value of pharmacogenetic testing in this vulnerable population.
No takes yet. Share an insight, caveat, or question.
May identify frail elderly needing intensified INR monitoring; leaves open whether genotyping improves outcomes in prospective studies.
Pautas et al. (2009) conducted a cohort in Frail elderly inpatients requiring warfarin (n=300). Multiple variant alleles (VKORC1, CYP2C9, CYP4F2, EPHX1) was evaluated on Overanticoagulation (INR >4) (OR 12.8, 95% CI 2.73-60.0). Multiple variant alleles in VKORC1 and CYP2C9 significantly increased the risk of overanticoagulation (INR >4) in frail elderly inpatients initiating warfarin (OR 12.8; 95% CI 2.73-60.0).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: